Sleep Management News & Media

Read and download below our recent news and media releases

Itamar Medical Announces Favorable CMS Reimbursement Decision to its WatchPAT™ Sleep Apnea Testing Device

Itamar Medical – Head Office, November 2018

Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea with a focus on the cardiology market, today announced the release of the 2019 Fee Schedule from the U.S.

Itamar Medical Highlights New WatchPAT™ Scoring Guidelines Based on the COMPASS(1) Study Results from Johns Hopkins Sleep Investigators at SLEEP 2018

Itamar Medical – Head Office, May 2018

Evidence-based guidelines based on a large-scale sleep apnea study demonstrating
WatchPAT’s efficiency and accuracy compared to standard diagnostic alternatives

Itamar Medical Launches SleePath™

Itamar Medical – Head Office, May 2018

Itamar Medical Launches SleePath™, an Integrated Cloud-based Sleep Apnea Patient Care Pathway Management Tool for AFib Patients at Heart Rhythm 2018

Airway Management Partners with Itamar Medical Ltd

Itamar Medical – Head Office, February 2018


Airway Management announced a new partnership with Itamar Medical Ltd to distribute the myTAP oral appliance.

FDA clearance for the new WatchPAT Central Plus

Itamar Medical – Head Office, June 2017

The new device will enable specific identification and reporting of Central Sleep Apnea (CSA).
With this new capability, patients suspected of having sleep apnea can be diagnosed more specifically with an exceptionally easy to use, automated and accurate WatchPAT HSAT device and benefit from optimized treatment. more

Endo-PAT system may help measure cardiovascular risk from breast cancer treatment

Itamar Medical – Head Office, 8 January 2017

SAN ANTONIO — The Endo-PAT2000 assay may be a simple way to measure vascular elasticity in outpatients after treatment with aromatase inhibitors, Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at the University of Minnesota, and a HemOnc Today Editorial Board member, told HemOnc Today at the San Antonio Breast Cancer Symposium. more

FDA Clears Expanded Indication for Itamar Medical’s WatchPAT Sleep Apnea Diagnostic Device for Adolescents

Itamar Medical – Head Office, 27 July 2016

Itamar Medical Reports Success in Clinical Study Validating WatchPAT for Central Sleep Apnea Differentiation, Submits Application for FDA Clearance of New WatchPAT Version

Itamar Medical – Head Office, 9 June 2016

Itamar Medical Offers a Total Sleep Apnea Management Solution to Cardiologists

Itamar Medical – Head Office, 13 May, 2015

Marketing Bulletin: Canada Youth WatchPAT

Itamar Medical – Head Office, 12 April 2016

EndoPAT distributor in China – Important Notice

Itamar Medical – Head Office, 26 April 2015

NEW EndoPAT exclusive distributor for the Chinese market.

Itamar Medical Launches WatchPAT Unified

Itamar Medical – Head Office, 09 June 2014

Click here to view Press Release

Itamar Medical’s EndoPAT Featured on the Doctor’s Channel

Itamar Medical – Head Office, 02 Mar 2014

Gilad Glick, CEO, Itamar Medical, introduces the Endopat 2000, an innovative device that can assess cardiac health in 15 minutes. more